OBJECTIVE: Human papillomavirus (HPV) vaccination has proven to be effective for prevention of HPV infection and HPV-associated precancerous cervical lesions.1 However, HPV vaccination rates have remained flat, and whether or not to vaccinate has become a social issue. In the United States in 2013, HPV vaccine coverage for girls ages 13-17 years was only 57%.2 A notable inhibitory factor to getting vaccinated has been reports of possible adverse effects. Safety concerns among US parents have increased (4.5% in 2008 to 16.4% in 2010), as have intentions not to vaccinate their daughters against HPV (39.8% in 2008 to 43.9% in 2010; odds ratio for trend, 1.08; 95% confidence interval, 1.04e1.13).3